Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Overview. First quarter 2026 results fell short of expectations. Startup delays for new projects and broader macroeconomic conditions caused the Building Solutions and Business Services divisions to perform worse than expected. The Energy Services division, however, maintained solid momentum. Star did see some significant new business wins and contract renewals in the quarter and realized merger synergies are running ahead of plan.
1Q26 Results. Revenue of $50.1 million was up 57.1% on a reported basis and up 7.7% on a pro forma basis. Top line, however, came in below our projection of $54 million, mostly due to the soft Business Services revenue. Adjusted EBITDA loss in 1Q26 increased to $1.6 million versus a loss of $0.7 million on a reported basis in 1Q25 and a loss of $1.2 million on a pro forma basis. We were at a positive adjusted EBITDA of $1.9 million. Net loss was $1.17 per share, and adjusted net loss was $0.99, compared to $0.59 and $0.38, respectively, in 1Q25.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Delayed filing and significant operating deterioration. Bitcoin Depot disclosed it is unable to timely file its Form 10-Q, citing unreasonable effort and expense, while preliminary fiscal Q1 2026 results reflected a sharp deterioration in operating performance driven by regulatory impacts and enhanced compliance controls.
Revenue and gross profit collapse. Revenue declined 49.2% year-over-year, falling by $80.7 million in the quarter, while gross profit declined 85.5% to $4.5 million from $31.2 million in the prior-year period, reflecting significantly lower transaction volumes and substantial margin compression.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Salem Media Group (OTCQX: SALM), one of America’s largest Christian and conservative multimedia companies, is heading private in a deal that underscores how mission alignment — not just financial metrics — is increasingly driving M&A activity in the small and microcap media space.
The Camarillo, California-based company announced on May 12 that it has entered into a definitive agreement to be acquired by WaterStone, formally known as The Christian Community Foundation, Inc. Under the terms of the deal, WaterStone will acquire all outstanding shares of Salem common stock at $1.00 per share — a premium of roughly 250% above the company’s recent trading price. The transaction is expected to close in August 2026, pending shareholder and regulatory approvals.
A Deal Decades in the Making
What makes this transaction particularly notable is the relationship that preceded it. WaterStone had already accumulated a 49.5% voting interest in Salem through prior preferred stock investments, making this less a hostile takeover and more the culmination of a long-term strategic partnership. The two organizations have collaborated on strategic initiatives for the past 18 months, and the acquisition process reportedly began in earnest roughly 24 months ago.
For investors and deal-watchers in the small and microcap universe, this structure is a textbook example of how insider relationships and mission alignment can shape deal dynamics in ways that pure financial engineering cannot. Rather than a traditional strategic buyer or private equity rollup, Salem is being absorbed by a values-aligned nonprofit foundation — a deal structure rarely seen at this scale in media.
Outperforming a Struggling Industry
The acquisition comes against a challenging backdrop for broadcast radio. According to Miller Kaplan data cited by the company, overall radio advertising revenue declined 3.4% in the first quarter. Salem, however, posted positive local radio growth of 2.8% during the same period, excluding the impact of recently divested stations — outpacing the broader industry by more than six percentage points.
That operational resilience, driven by Salem’s programming strength and its deeply loyal advertiser and ministry relationships, likely supported the valuation discussion and helped justify the premium WaterStone was willing to pay.
What Goes Private
Salem operates a diversified media platform spanning national radio, digital properties, streaming, podcasting, television, and publishing. The company’s conservative and Christian content reaches millions of consumers monthly across all these verticals, giving it a rare combination of audience loyalty and cross-platform reach that is increasingly difficult to build from scratch.
Taking the company private removes Salem from the volatility of the OTCQX market and gives WaterStone the operational control to execute on a longer-term mission without the pressures of quarterly earnings cycles.
The Bigger Picture for Small-Cap Media
For the broader small and microcap media landscape, the Salem deal is a signal worth watching. As traditional broadcast continues navigating structural headwinds, buyers willing to pay a substantial premium for niche, mission-aligned audience loyalty are emerging as a distinct class of acquirers. Whether that signals a broader wave of similar transactions remains to be seen, but Salem’s deal makes a compelling case that brand identity and audience trust carry real valuation weight — even in a challenged sector.
The transaction was unanimously approved by Salem’s Board of Directors.
Copper is back above $14,000 a metric ton and closing in on its all-time high, and the forces driving this rally are not short-term noise. For small and microcap investors, the more relevant conversation is what happens to the junior miners when the red metal runs.
Prices on the London Metal Exchange climbed as high as $14,106 a ton Tuesday — within striking distance of the all-time high of $14,527 set in January. The move comes despite a fragile geopolitical backdrop, as the ongoing Iran conflict continues to cloud the global growth outlook. Copper is up roughly 13% year-to-date, a run that few predicted given the macro headwinds that dominated early 2026.
Why Copper Is Running
The rally is being driven by a confluence of factors that show no signs of reversing. Chinese industrial demand has rebounded meaningfully after a sluggish start to the year, tightening physical supply pipelines. At the same time, Middle Eastern conflict has squeezed sulfur supplies — a key input in certain copper production processes — adding an upstream constraint that is putting additional pressure on an already tight market.
Supply disruptions at major copper mines across Africa and Indonesia have compounded the picture. Ore grades at legacy mines continue to decline — the average grade across the top 20 copper mines globally has fallen roughly 9% over the past two decades — and there are few meaningful new projects with near-term production timelines to offset that degradation.
Analysts are taking notice. A mining analyst at Scotiabank now projects the global copper market will run a deficit of 350,000 tons by 2027, a dramatic revision from a roughly balanced market forecast just two months ago. J.P. Morgan has a similar view, projecting a refined copper shortfall of approximately 330,000 metric tons in 2026. Goldman Sachs has labeled copper a core target of what it calls the AI and electrification supercycle — and the numbers support that framing. Each electric vehicle requires four to five times the copper of a traditional internal-combustion vehicle, and hyperscale AI data centers are adding millions of tonnes of incremental demand to forecasts through 2030.
The Junior Miner Angle
For ChannelChek’s audience, the large-cap copper story — Freeport, BHP, Southern Copper — is well-covered elsewhere. The more compelling conversation is at the junior and small-cap level, where price leverage to copper is most pronounced. When copper moves, junior miners tend to move harder and faster, because their economics are highly sensitive to spot prices.
Names like HudBay Minerals (HBM), Capstone Copper, and Foran Mining sit in the small-to-mid cap range and carry significant operational leverage to sustained copper pricing above $13,000 a ton. For investors seeking a basket approach to junior copper exposure, the Sprott Junior Copper Miners ETF (COPJ) tracks mid-, small-, and microcap companies across the copper mining universe and has gained significant traction as copper’s structural story has matured.
The broader thesis is straightforward: copper demand is structural, driven by electrification, AI infrastructure, and defense modernization. Supply is challenged, fragile, and years away from meaningful new capacity. That combination — tight supply meeting accelerating demand — is precisely the environment where smaller, earlier-stage copper producers and developers tend to generate the most asymmetric upside.
With the preliminary list of copper supply constraints only growing and prices pressing near records, this is a space worth watching closely.
Net Income and Operating Income Reported for Third Consecutive Quarter Revenues, Net Income and Adjusted EBITDA Exceed High End of Guidance Tenth Consecutive Quarter of Positive Adjusted EBITDA
EL SEGUNDO, Calif.–(BUSINESS WIRE)– The Beachbody Company, Inc. (NASDAQ: BODi) (“BODi” or the “Company”), the proactive wellness company delivering nutrition, supplements, and proven fitness programs that help people take control of their health inside and out, today announced financial results for its first quarter ended March 31, 2026.
“Q1 marks our third consecutive quarter of profitability on both net income and operating income, validating the strength of our transformed business model,” said Carl Daikeler, co-founder and BODi’s Chief Executive Officer. “We’re now deploying this efficient platform to capitalize on a major market opportunity in nutrition, a massive global category that’s more than 12 times the size of digital fitness. With attractively priced supplements under iconic brands like P90X and Shakeology, we can acquire nutrition customers and seamlessly migrate them to our digital fitness platform, delivering the Total Solution that has always driven our best customer results.”
“Our strong balance sheet and substantially improved financial position provide the flexibility to fund our retail expansion and innovation pipeline,” said Mark Goldston, BODi’s Executive Chairman. “With ten consecutive quarters of positive Adjusted EBITDA and a dramatically lowered breakeven point that creates massive operating leverage, we’ve built a resilient financial foundation that positions us to capitalize on significant growth opportunities in both nutrition and digital fitness.”
First Quarter 2026 Results
Total revenue was $54.3 million compared to $72.4 million in the prior year period.
Digital revenue was $33.6 million compared to $42.9 million in the prior year period and digital subscriptions totaled 0.81 million in the first quarter.
Nutrition and Other revenue was $20.7 million compared to $28.7 million in the prior year period and nutritional subscriptions totaled 0.06 million in the first quarter.
Connected Fitness revenue was $0.0 million compared to $0.8 million in the prior year period as we ceased the sale of bike inventory in the first quarter of 2025.
Gross margin was 71.8% compared to 71.2% in the prior year period.
Total operating expenses were $35.9 million compared to $55.2 million in the prior year period.
Operating income improved by $6.8 million to $3.1 million, the Company’s third consecutive quarter of operating income, compared to an operating loss of $3.7 million in the prior year period.
Net income was $2.3 million, the Company’s third consecutive quarter of net income, compared to a net loss of $5.7 million in the prior year period.
Adjusted EBITDA 1 was $8.0 million compared to $3.7 million in the prior year period.
Adjusted net income 1 was $2.5 million compared to a loss of $5.1 million in the prior year period.
Cash used in operating activities for the three months ended March 31, 2026 was $1.0 million compared to cash provided by operating activities of $2.3 million in the prior year period, and cash used in investing activities was $0.7 million compared to cash used in investing activities of $0.7 million in the prior year period. Free cash flow 1 was $(1.7) million compared to $1.6 million in the prior year period.
1Definitions of (1) Adjusted EBITDA, (2) adjusted net income (loss), (3) free cash flow and (4) net cash position, and reconciliations to the comparable GAAP metrics, are at the end of this release.
Key Operational and Business Metrics
Outlook for The Second Quarter of 2026
Conference Call and Webcast Information
BODi will host a conference call at 5:00 pm ET on Tuesday, May 12, 2026, to discuss its financial results and matters other than past results, such as guidance. To participate in the live call, please dial (833) 461-5787 (U.S. & Canada) and provide the conference identification number: 684011158. The conference call will also be available to interested parties through a live webcast at https://investors.thebeachbodycompany.com/.
After the conference call, a webcast replay will remain available on the investor relations section of the Company’s website for one year.
About BODi and The Beachbody Company, Inc.
BODi is a proactive wellness company delivering nutrition, supplements, and proven fitness programs that help people take control of their health inside and out. With nearly three decades of experience, BODi, formerly Beachbody, has evolved from a leader in home fitness into a comprehensive health and fitness ecosystem designed to help people achieve their goals and lead healthier, more fulfilling lives. Anchored by science-backed nutrition solutions like Shakeology and supported by its portfolio of proven fitness and habit-building programs, including P90X and INSANITY, BODi is creating a more accessible and effective path to long-term health. Since its inception, BODi has supported more than 30 million customers in achieving lasting results. The company continues to innovate across nutrition and digital fitness to deliver simple, proven solutions for modern lifestyles. For more information, please visit TheBeachBodyCompany.com.
Safe Harbor Statement
This press release of The Beachbody Company, Inc. (“we,” “us,” “our,” and similar terms) contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are statements other than statements of historical facts and statements in future tense. These statements include but are not limited to, statements regarding our future performance and our market opportunity, including expected financial results for the second quarter and full year, our business strategy, our plans, and our objectives and future operations.
Forward-looking statements are based upon various estimates and assumptions, as well as information known to us as of the date hereof, and are subject to risks and uncertainties. Accordingly, actual results could differ materially due to a variety of factors, including: our ability to effectively compete in the fitness and nutrition industries; our ability to successfully acquire and integrate new operations; our reliance on a few key products; market conditions and global and economic factors beyond our control; intense competition and competitive pressures from other companies worldwide in the industries in which we operate; and litigation and the ability to adequately protect our intellectual property rights. You can identify these statements by the use of terminology such as “believe”, “plans”, “expect”, “will”, “should,” “could”, “estimate”, “anticipate” or similar forward-looking terms. You should not rely on these forward-looking statements as they involve risks and uncertainties that may cause actual results to vary materially from the forward-looking statements. For more information regarding the risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements, as well as risks relating to our business in general, we refer you to the “Risk Factors” section of our Securities and Exchange Commission (“SEC”) filings, including those risks and uncertainties included in the Form 10-K filed with the SEC on March 10, 2026 and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, which are available on the Investor Relations page of our website at https://investors.thebeachbodycompany.com and on the SEC’s website at www.sec.gov.
All forward-looking statements contained herein are based on information available to us as of the date hereof and you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance, or achievements. We undertake no obligation to update any of these forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or revised expectations, except as required by law. Undue reliance should not be placed on forward-looking statements.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for F351 (hydronidone) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). The acceptance comes after the NMPA previously granted priority review status for F351 in March after Gyre submitted the NDA through its majority-owned subsidiary Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals). This marks the second major product for which Gyre has submitted an NDA to the NMPA, and is a significant milestone for the Company in the commercialization of a new medication for the treatment of CHB-induced liver fibrosis.
Dr. Ying Luo, President and Chief Executive Officer of Gyre, commented, “This is another significant achievement for Gyre. This NDA is our third submission accepted for review by the NMPA, and the first one for our F351 program. Our interactions with the CDE have been very positive to date, reinforcing the agency’s support for addressing the medical need to treat liver fibrosis and the potential of F351 as an innovative therapeutic option. If approved, F351 could address the tens of millions of patients in China with HBV infection, many of whom will develop liver fibrosis and potentially cirrhosis. We look forward to working closely with CDE to progress F351 towards commercial approval.”
About Priority Review Designation by the NMPA in China
Priority review was established in China in 2017 to facilitate drug registration and accelerate the development of new drugs with clinical value under the guidance of Opinions on Encouraging Pharmaceutical Innovation via Priority Review & Approval. According to these guidelines, the NMPA will prioritize the review of these applications and allocate additional evaluation resources, which is expected to accelerate the review process.
About F351 (hydronidone)
F351 is Gyre’s lead development candidate for the treatment of liver fibrosis that is being developed for two different indications. It is a structurally modified derivative of pirfenidone designed to optimize metabolic properties while targeting the TGF-β1 signaling pathway, a key mediator of fibrogenesis. Gyre is developing F351 for two primary indications: Chronic hepatitis B (CHB)-associated liver fibrosis in the People’s Republic of China (PRC) and MASH-associated liver fibrosis initially in the United States.
In the United States, Gyre has completed a Phase 1 clinical trial in healthy volunteers evaluating F351’s safety, tolerability, and PK. Gyre plans to file an Investigational New Drug (IND) application in the U.S. by the end of 2026, and, if the IND becomes effective, to initiate a Phase 2 clinical trial.
About CHB-Induced Liver Fibrosis
Liver fibrosis is a condition where healthy tissues in the liver become scarred in response to chronic inflammation. If left untreated, it can progress to cirrhosis—the final, severe stage where extensive scarring permanently distorts the liver’s architecture and significantly impairs its vital functions. Viral hepatitis is estimated to cause up to 50% of fibrosis and 65% of cirrhosis worldwide. Without intervention, liver fibrosis and cirrhosis typically progress from manageable organ damage to systemic, life-threatening liver failure and hepatocellular carcinoma (HCC). No non-viral directed therapy has been shown to reduce fibrosis in viral induced hepatitis.
About Gyre Pharmaceuticals
Gyre Pharmaceuticals Co., Ltd., a subsidiary of Gyre Therapeutics, Inc., is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY™ (pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share over the past several years. In addition, Gyre Pharmaceuticals’ pipeline includes F351 (hydronidone), a structural analogue of pirfenidone, which demonstrated statistically significant fibrosis regression after 52 weeks of treatment in a pivotal Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC. F351 received Breakthrough Therapy designation by the CDE of the NMPA in March 2021. Gyre Pharmaceuticals is also developing treatments for PD, RILI with or without immune-related pneumonitis, COPD, PAH and ALF/ACLF. As of March 31, 2026, Gyre Therapeutics owns a 69.7% equity interest in Gyre Pharmaceuticals.
About Gyre Therapeutics
Gyre Therapeutics is a commercial-stage biopharmaceutical company headquartered in San Diego, CA focused on the development and commercialization of small-molecule therapeutics with its most advanced programs addressing organ fibrosis and inflammatory diseases.
Gyre’s wholly-owned subsidiary, Cullgen Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader-antibody conjugate (DAC) therapies for critical conditions including cancer and inflammatory diseases. Cullgen has created a portfolio of highly selective targeted protein degrader and DAC product candidates designed to potently and efficiently eliminate therapeutically relevant proteins in patients.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: the development and commercial potential and potential benefits of F351; the timing and progression of commercial approval of F351; and the timing of Gyre’s IND application in the U.S., and, if the IND becomes effective, initiation of a Phase 2 clinical trial for F351. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: unexpected costs, charges or expenses resulting from the acquisition; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the acquisition; the risk that the combined company may not be able to successfully integrate the businesses and realize the expected benefits of the acquisition in a timely manner or at all; the uncertainties associated with Gyre’s and Cullgen’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; risks related to the inability of the combined entity to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the possible failure to realize certain anticipated benefits of the acquisition, including with respect to future financial and operating results. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 13, 2026, and in other filings with the Securities and Exchange Commission.
Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026
Commercial readiness activities continue in anticipation of the potential commercial launch of OLC
MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update.
“As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “Our ongoing dialogue with the FDA during the review cycle has been constructive and timely. Uncontrolled hyperphosphatemia remains a significant health concern, affecting nearly 75% of U.S. patients with chronic kidney disease who are undergoing dialysis. OLC has the potential to improve adherence and phosphorus control with reduced pill burden, compared with currently available phosphate binders.”
Key Highlights & Upcoming Milestones
In January 2026, the Company announced the FDA accepted the resubmission of its NDA for OLC, an investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with CKD on dialysis. The FDA set a PDUFA target action date of June 29, 2026. The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study in patients with CKD on dialysis), multiple preclinical studies, and chemistry, manufacturing, and controls (CMC) data. The FDA did not raise any concerns regarding the preclinical, clinical, or safety data for OLC included in the original NDA submission. The December 2025 resubmission was based on progress made by the third-party manufacturing vendor responsible for the drug product.
In preparation for a potential launch of OLC later this year, the Company continues to strengthen its commercial infrastructure and advance market readiness initiatives. Unicycive’s goal is to optimize patient access across all reimbursement settings and intends to provide dedicated access and reimbursement support services for all patients through Unicycive’s UniSource™ reimbursement hub.
Financial Results for the Quarter Ended March 31, 2026
As of May 11, 2026, unaudited cash, cash equivalents, and marketable securities totaled $57.1 million. The Company believes that it has sufficient resources to fund planned operations into 2027.
Research and Development (R&D) expense were $1.6 million for the quarter ended March 31, 2026, compared to $2.2 million for the three months ended March 31, 2025. The decrease in research and development expense was primarily attributed to a decrease in drug development costs as well as consulting and professional fees.
General and Administrative (G&A) expense were $6.8 million for the quarter ended March 31, 2026, compared to $5.8 million for the three months ended March 31, 2025. The increase was primarily attributed to an increase in consulting, professional services, and labor costs.
Other income (expense) was $(4.4) million for the quarter ended March 31, 2026, compared to $8.6 million income for the three months ended March 31, 2025, attributed primarily to an increase in the fair value of the Company’s warrant liability.
Net comprehensive income (loss) attributable to common stockholders, basic for the quarter ended March 31, 2026, was $(12.8) million, or $(0.54) per share of common stock, compared to $0.5 million income, or $0.04 per share of common stock, for the three months ended March 31, 2025. Net comprehensive income (loss) attributable to common stockholders, diluted for the quarter ended March 31, 2026, was $(12.8) million, or $(0.54) per share of common stock, compared to $(6.2) million, or $(0.50) per share of common stock, for the three months ended March 31, 2025. The increased net loss for the quarter ended March 31, 2026, was attributed primarily to an increase in the fair value of the Company’s warrant liability.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Revenue: $723M, down 3.7%. Growth in Government and Transportation segments
Pre-tax Income (Loss): $(27)M, improved by $29M year-over-year
Adj. EBITDA(1): $49M, improved by $12M year-over-year
Adj. EBITDA Margin(1): 6.8%, improved by 190 bps year-over-year
Cash flow from operating activities: $(8)M, improved by $50M year-over-year
New Business Signings ACV(2): $114M, improved by $5M year-over-year
FLORHAM PARK, N.J., May 11, 2026 — Conduent Incorporated (Nasdaq: CNDT), a global technology driven business process solutions and services company, today announced its first quarter 2026 financial results.
Harsha V. Agadi, Chief Executive Officer, stated, “Q1 2026 marked the start of a rapid and sustainable transformation at Conduent. In the quarter we started to develop a comprehensive cost reduction and technology optimization strategy. In addition, we enhanced our go-to-market approach, all while driving an improvement in our operating model, achieving EBITDA margins of 6.8% for the quarter, and generated a significant year‑over‑year improvement in adjusted free cash flow. Looking ahead to 2027, we see a clear path to positive adjusted free cash flow and continued improvement in adjusted EBITDA.”
“We also took decisive steps to strengthen execution. In April, I streamlined leadership of our Commercial organization to sharpen accountability and accelerate decision‑making, aligning client relationships and sales execution under a simplified reporting structure that reports directly to me.”
“Portfolio optimization remains a critical pillar of our turnaround. I am extremely confident we will be able to reduce complexity, improve operating performance and continue to strengthen our balance sheet as we use proceeds to reduce debt.”
Agadi continued, “Our priorities are clear: accelerating execution, enforcing financial discipline, reducing our cost structure, optimizing the portfolio, converting pipeline into growth, and simplifying the organization. In Q1, we made meaningful, sustainable progress across each of these priorities, and we are building momentum as we move forward.”
Key Financial Q1 2026 Results
Performance Commentary At the end of the first quarter of 2026, Conduent maintained a cash balance of $228 million along with $190 million of unused capacity under its credit facility.
Q1 2026 pre-tax income (loss) was $(27) million versus $(56) million in the prior year period. This improvement was primarily caused by the absence of the discrete event-related costs from the prior year.
Q1 2026 Adjusted EBITDA of $49 million and Adjusted EBITDA margin of 6.8% increased, respectively, versus the prior year.
Revenue benefited from continued strength in Government and Transportation, with Government up approximately $10 million and Transportation up approximately $3 million year‑over‑year, reflecting solid demand and execution across both segments.
Cash flow from operating activities increased by $50 million year‑over‑year, reflecting a clear improvement from the prior year period.
Sales momentum continued to strengthen, with New Business ACV of $114 million for the quarter and the qualified pipeline expanding to approximately $3.5 billion, up from $3.2 billion in the prior year period, reinforcing improved growth visibility.
Key Achievements and Industry Accolades
Business Execution & Contract Wins
Medicaid Enterprise Systems and Fiscal Agent Services renewal for up to 14 years, expanding a multi-decade partnership to modernize claims processing, finance, and customer operations
5-year Centralized Collections Processing Unit renewal for a state child support program, extending a 25+ year relationship and digital payment capabilities
Expanded relationships with 20–25+ year healthcare clients, including new geographies and additional lines of business across customer experience, payment integrity, and analytics
Industry Recognition & Market Positioning
Named a Leader in the 2026 Healthcare Payer Agility & Innovation NEAT Evaluation by NelsonHall, reflecting ability to deliver near-term value while supporting payer transformation
Named a Leader in the 2026 Healthcare Payer Intelligent Operations PEAK Matrix® Assessment by Everest Group, highlighting AI, automation, and platform-led capabilities
Named to the 2026 GovTech 100 list by Government Technology magazine and GovTech.com for the fifth consecutive year, recognizing leadership in improving digital government services
Thought Leadership & Ecosystem Partnerships
Co-authored “Humanizing Human Resources: The 2026 State of Experience in the New World of Work” with Mercer, showing that employees who feel valued and recognized drive higher satisfaction, engagement, and retention
Published findings from Conduent’s 2026 “Blueprint for Smarter Health” survey, highlighting employer challenges in balancing rising benefits costs with employee expectations, and the role of AI in addressing both concerns
Operational Excellence & Delivery
Customer Experience team in the Philippines received the Trailblazer Award from a leading telecommunications provider, recognizing proactive, data-driven customer engagement through social listening and outreach
FY 2026 and 2027 Outlook(3)
Conference Call Management will present the results during a conference call and webcast on May 11, 2026 at 5:00 p.m. ET.
The call will be available by live audio webcast along with the news release and online presentation slides at https://investor.conduent.com/.
The conference call will also be available by calling 877-407-4019 toll-free. If requested, the conference ID for this call is 13760102.
The international dial-in is 1-201-689-8337. The international conference ID is also 13760102.
A recording of the conference call will be available by calling 1-877-660-6853 three hours after the conference call concludes. The replay ID is 13760102.
The telephone recording will be available until May 25, 2026
About Conduent Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 48,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $80 billion in government payments annually, enabling approximately 2.0 billion customer service interactions annually, empowering millions of employees through HR services every year and processing over 14 million tolling transactions every day. Learn more at www.conduent.com.
Non-GAAP Financial Measures We have reported our financial results in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP). In addition, we have discussed our financial results using non-GAAP measures. We believe these non-GAAP measures allow investors to better understand the trends in our business and to better understand and compare our results. Accordingly, we believe it is necessary to adjust several reported amounts, determined in accordance with U.S. GAAP, to exclude the effects of certain items as well as their related tax effects. Management believes that these non-GAAP financial measures provide an additional means of analyzing the results of the current period against the corresponding prior period. However, these non-GAAP financial measures should be viewed in addition to, and not as a substitute for, our reported results prepared in accordance with U.S. GAAP. Our non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable U.S. GAAP measures and should be read only in conjunction with our Consolidated Financial Statements prepared in accordance with U.S. GAAP. Our management regularly uses our non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. Providing such non-GAAP financial measures to investors allows for a further level of transparency as to how management reviews and evaluates our business results and trends. These non-GAAP measures are among the primary factors management uses in planning for and forecasting future periods. Compensation of our executives is based in part on the performance of our business based on certain of these non-GAAP measures. Refer to the “Non-GAAP Financial Measures” and “Non-GAAP Reconciliations” sections attached to this release for a discussion of these non-GAAP measures and their reconciliation to the reported U.S. GAAP measures.
Forward-Looking Statements This press release, any exhibits or attachments to this release, and other public statements we make may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “expectations,” “in front of us,” “plan,” “intend,” “will,” “aim,” “should,” “could,” “forecast,” “target,” “may,” “continue to,” “looking to continue,” “endeavor,” “if,” “growing,” “projected,” “potential,” “likely,” “see,” “ahead,” “further,” “going forward,” “on the horizon,” “as we progress,” “going to,” “path from here forward,” “think,” “path to deliver,” “from here,” “on track,” “remain” and similar expressions (including the negative and plural forms of such words and phrases), as they relate to us, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact included in this press release or any attachment to this press release are forward-looking statements, including, but not limited to, statements regarding our financial results, condition and outlook; changes in our operating results; general and market and economic conditions; and our projected financial performance, including all statements made under the section captioned “FY 2026 and Mid-Term Outlook” within this release. These statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, many of which are outside of our control, that could cause actual results to differ materially from those expected or implied by such forward-looking statements contained in this press release, any exhibits to this press release and other public statements we make.
Important factors and uncertainties that could cause our actual results to differ materially from those in our forward-looking statements include, but are not limited to: government appropriations and termination rights contained in our government contracts, the competitiveness of the markets in which we operate and our ability to renew commercial and government contracts, including contracts awarded through competitive bidding processes; our ability to recover capital and other investments in connection with our contracts; the impact of geopolitical events and geopolitical tensions (such as the war in Ukraine and conflict in the Middle East), macroeconomic conditions, natural disasters and other factors in a particular country or region on our workforce, customers and vendors; our reliance on third-party providers; our ability to deliver on our contractual obligations properly and on time; changes in continued interest in outsourced business process services; the adverse effect of claims of infringement of third-party intellectual property rights; our ability to estimate the scope of work or the costs of performance in our contracts; the loss of key senior management and our ability to attract and retain necessary technical personnel and qualified subcontractors; our failure to develop new service offerings and protect our intellectual property rights; our ability to modernize our information technology infrastructure and consolidate data centers; expectations relating to environmental, social and governance considerations; utilization of our stock repurchase program; the effects related to our use of artificial intelligence on our business; the failure to comply with laws relating to individually identifiable information and personal health information; the failure to comply with laws relating to processing certain financial transactions, including payment card transactions and debit or credit card transactions; breaches of our information systems or security systems or any service interruptions; risks related to hacking or other cybersecurity threats to our data systems, information systems and network infrastructure and other service interruptions, including relating to the previously disclosed cyber event that took place in January 2025 (the “January 2025 Cyber Event”), including Conduent’s investigation of such incident and mitigation and remediation efforts, the nature and extent of such incident, the potential disruption to our business or operations, the potential impact on Conduent’s reputation, and Conduent’s assessments of the likely financial and operational impacts of such incident; our ability to comply with data security standards; developments in various contingent liabilities that are not reflected on our balance sheet, including those arising as a result of being involved in a variety of claims, lawsuits, investigations and proceedings; risks related to divestiture transactions, including but not limited to the Company’s ability to realize the benefits anticipated from such transactions, and unexpected costs or liabilities in connection with such transactions, the impact of potential goodwill and other asset impairments on our results of operations; our significant indebtedness and the terms of such indebtedness; our failure to obtain or maintain a satisfactory credit rating and financial performance; our ability to obtain adequate pricing for our services and to improve our cost structure; our ability to collect our receivables, including those for unbilled services; a decline in revenues from, or a loss of, or a reduction in business from or failure of significant clients; fluctuations in our non-recurring revenue; increases in the cost of voice and data services or significant interruptions in such services; our ability to receive dividends or other payments from our subsidiaries; and other factors that are set forth in the “Risk Factors” section, the “Legal Proceedings” section, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other sections in our 2025 Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with or furnished to the Securities and Exchange Commission. Any forward-looking statements made by us in this release speak only as of the date on which they are made. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether because of new information, subsequent events or otherwise, except as required by law.
Rank Day is behind us. On April 30, FTSE Russell locked in the closing market capitalizations that will determine which companies get added to, removed from, or shuffled between the Russell 1000, Russell 2000, Russell 3000, and Russell Microcap indexes. The data is set. What comes next is where investor attention needs to be focused.
The first preliminary additions and deletions list publishes on May 22 — ten days from today — after 6 PM ET. If you’ve been following our coverage of this year’s reconstitution, you already know why 2026 carries more structural weight than any reconstitution in decades. If you’re just catching up, start here: Russell Reconstitution 2026 — What Investors Should Know and Rank Day Coverage.
Here’s what’s changed since April 30 and why it matters.
The Market Has Moved Since Rank Day
The twelve days since rank day have not been quiet. This morning, the Bureau of Labor Statistics reported April CPI came in at 3.8% year-over-year, with energy prices surging 3.8% in a single month on the back of ongoing Middle East conflict and elevated oil above $100 a barrel. Rate cut expectations for 2026 have effectively been wiped off the table. Consumer sentiment sits near historic lows.
At the same time, small caps have been dealing with a bifurcated environment — some sectors, particularly defense and domestic manufacturing, have seen meaningful appreciation, while rate-sensitive and consumer-facing names continue to struggle. That divergence matters enormously in a reconstitution year, because companies near the market cap breakpoints on April 30 may have landed in very different positions than they would have a month earlier.
What the Preliminary Lists Could Show
The market volatility of the past twelve months has reshuffled market caps across the small and microcap universe more dramatically than most years. That sets up for a higher-than-normal number of index movers — companies graduating to the Russell 1000, falling into the Russell 2000, or dropping out of the Russell indexes entirely. Defense and energy-adjacent names that have appreciated significantly may be candidates for upward migration. On the other side, consumer discretionary and rate-sensitive small caps that have seen compression could face demotion or deletion.
The stocks to watch most closely are those sitting right at the boundary between indexes. For companies near the Russell 1000/2000 breakpoint, passive fund flows triggered by an index move can be substantial — and the price action in the weeks following the preliminary list often front-runs the actual reconstitution.
The Window That Matters Most
The preliminary list on May 22 is the starting gun, not the finish line. Updated lists follow on May 29, June 5, June 12, and June 18. The lock-down period — when membership is considered final — begins June 8. Reconstitution takes effect after the close on June 26.
That means the actionable window for investors runs from the moment the first preliminary list drops through the lockdown on June 8. Historically, the most significant price moves around reconstitution happen in this period, not on recon day itself. By the time June 26 arrives, passive funds benchmarked to Russell indexes are simply executing what the market has largely already priced in.
With more than $12 trillion benchmarked to Russell U.S. Equity indexes, the capital flows triggered by even a single significant addition or deletion can be meaningful — especially for smaller companies with lower liquidity.
Channelchek will be covering the May 22 preliminary list in detail as it’s released. Ten days. Watch this space.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q1 Meets Expectations. Net revenue of $96.8 million and adjusted EBITDA of $16.4 million were in line, while digital advertising accelerated to 6.8% growth and programmatic advertising increased an impressive 21% year-over-year.
Digital remains the key growth driver. Its differentiated digital platform separates it from traditional radio peers, with digital businesses generating a record 59% of total revenue and 63% of total segment profit. Programmatic advertising, media partnerships, and direct sales digital assets are all performing strongly, while the rapidly scaling white-label media partnership initiative could become a meaningful long-term contributor to growth.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Overview. The first quarter of 2026 was the 9th consecutive quarter of year-over-year revenue growth, with the quarter generating record revenue for the Company. SKYX is continuing its growth despite the slow new-build market that is affecting smart home, lighting, and home decor segments. This bodes well for when the markets eventually turn, in our view.
1Q26 Results. Record 1Q26 revenue of $22.1 million, up 9.8% over 1Q25 revenue of $20.1 million. Gross margin improved 160bp to 30% from 28.4% in the year-ago period. Net loss of $9.5 million was up slightly from a net loss of $9.3 million in 1Q25, driven by higher G&A expenses, although on a per share basis, net loss declined to $0.07 from $0.09. Adjusted EBITDA was a negative $3.8 million in 1Q26 compared to a negative $3.6 million last year.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Income Statement. Our note yesterday reviewing Kelly’s first quarter operating results and updated projections went out with the incorrect updated income statement projections table. The numbers in the body of the report are correct. We have attached the correct updated model.
Maintaining Outperform. We are maintaining our Outperform rating and $17 price target. While it will take some time to see what changes Hunt will bring to Kelly, we believe the shares are oversold and present a positive risk/reward opportunity. Diversification into higher growth, higher margin specialties, and the benefits acquired from the expansion are significant assets that have repositioned the Company, in our view.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
1Q 2026 financial results. InPlay Oil generated first-quarter 2026 adjusted funds flow (AFF) of C$30.1 million, or C$1.08 per share, above our estimate of C$27.4 million, or C$0.98 per share. Oil and natural gas sales revenue totaled C$88.4 million, ahead of our C$79.9 million forecast, due to stronger commodity prices. First quarter production averaged 18,337 barrels of oil equivalent per day (boe/d), modestly below our estimate. Compared to the prior year period, production, oil and natural gas sales revenue, operating income, and AFF increased 127.1%, 102.0%, 116.9%, and 79.6%, respectively. Average production more than doubled due to the successful integration of the company’s 2025 acquisition and strong results from its Pembina drilling program. Liquids production increased significantly, improving the overall production mix and supporting stronger corporate netbacks.
Outlook for the remainder of 2026. Supported by stronger oil prices, the Company increased its adjusted funds flow and free adjusted funds flow guidance to a range of C$143.0 to C$151.0 million, compared to previous expectations of C$122.0 million to C$129.0 million, while maintaining a disciplined production target of 18,600 to 19,200 boe/d and capital spending in the range of C$66.0 to C$74.0 million.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
